Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen Other stock markets			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

24-05-30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
22-06-28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	10.46B 67.63B 9.05B 8.44B 7.75B 14.57B 995B 14.8B 99.07B 38.84B 499B 39.26B 38.4B 1,649B	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	10.49B 67.82B 9.07B 8.47B 7.77B 14.61B 998B 14.84B 99.35B 38.95B 500B 39.37B 38.51B 1,654B	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

24-05-30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
22-06-28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
21-04-25	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
20-02-17	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
20-02-07	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
20-01-30	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
20-01-30	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
20-01-13	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
19-11-25	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
19-11-24	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
19-11-13	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
19-11-12	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
19-10-30	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

21-06-02	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
20-02-17	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
20-01-29	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
20-01-27	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
20-01-27	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Stock

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news : Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	2017-09-12
Stacy Wheeler COO	Chief Operating Officer	-	2016-02-29

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
MERCK & CO., INC.	+0.16%	-1.24%	+59.99%	+21.20%	318B
MERCK KGAA	-1.03%	+0.35%	+37.33%	-10.25%	72.2B
HALOZYME THERAPEUTICS, INC.	+20.24%	+24.93%	+66.05%	+145.47%	12.23B
KYOWA KIRIN CO., LTD.	+1.29%	-0.31%	-5.23%	-4.32%	8.45B
SK BIOPHARMACEUTICALS CO., LTD.	+2.28%	+8.10%	-14.26%	-6.67%	4.75B
BETTA PHARMACEUTICALS CO., LTD.	+14.37%	+22.10%	+4.12%	+59.93%	4.38B
YUHAN CORPORATION	+3.60%	+9.66%	-28.16%	+15.93%	4.26B
SUPERNUS PHARMACEUTICALS, INC.	+1.88%	+6.74%	+14.91%	+47.72%	2.77B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+4.26%	+0.31%	+0.91%	-0.41%	2.26B
Average	+4.70%	+7.38%	+15.07%	+29.84%	43.05B
Weighted average by Cap.	+0.79%	+0.34%	+52.19%	+19.04%

	2017	2018
Net sales	30.17M 195M 26.1M 24.36M 22.37M 42.05M 2.87B 42.69M 286M 112M 1.44B 113M 111M 4.76B	39.49M 255M 34.17M 31.9M 29.28M 55.05M 3.76B 55.89M 374M 147M 1.88B 148M 145M 6.23B
Net income	-9.54M -61.72M -8.26M -7.71M -7.07M -13.3M -908M -13.5M -90.42M -35.44M -455M -35.83M -35.05M -1.51B	-5.28M -34.18M -4.57M -4.27M -3.92M -7.37M -503M -7.48M -50.08M -19.63M -252M -19.84M -19.41M -834M
Net Debt	18.05M 117M 15.62M 14.58M 13.38M 25.16M 1.72B 25.54M 171M 67.05M 861M 67.78M 66.3M 2.85B	29.38M 190M 25.43M 23.73M 21.79M 40.96M 2.8B 41.58M 278M 109M 1.4B 110M 108M 4.64B